Drug Profile
FR 901533
Latest Information Update: 17 Feb 2006
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Shiga University of Medical Science
- Class Heart failure therapies
- Mechanism of Action Endothelin-converting enzyme 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure